Hunan Er Kang Pharmaceutical (300267) — Tangible Net Worth Ratio
Hunan Er Kang Pharmaceutical (300267) has a Tangible Net Worth Ratio of 92.0% as of June 2025. This metric is calculated by deducting intangible assets (CN¥353.85 Million) from net assets (CN¥4.42 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore net asset growth rate of Hunan Er Kang Pharmaceutical to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Hunan Er Kang Pharmaceutical Tangible Net Worth Ratio (2008–2024)
This chart shows how Hunan Er Kang Pharmaceutical's Tangible Net Worth Ratio has changed across 17 annual periods from 2008 to 2024. As of June 2025, the ratio stands at 92.0%, reflecting net assets of CN¥4.42 Billion with intangible assets of CN¥353.85 Million CNY. For live market cap and overall valuation, see how much is Hunan Er Kang Pharmaceutical worth.
Annual Tangible Net Worth Ratio for Hunan Er Kang Pharmaceutical (2008–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for Hunan Er Kang Pharmaceutical from 2008 to 2024, covering 17 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. Explore Hunan Er Kang Pharmaceutical (300267) reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 91.7% | CN¥4.40 Billion | CN¥363.56 Million | CN¥5.20 Billion | ▼ -0.4 pp |
| 2023 | 92.1% | CN¥4.81 Billion | CN¥378.03 Million | CN¥5.48 Billion | ▲ +0.2 pp |
| 2022 | 92.0% | CN¥5.05 Billion | CN¥406.14 Million | CN¥5.86 Billion | ▲ +0.8 pp |
| 2021 | 91.1% | CN¥4.87 Billion | CN¥431.45 Million | CN¥5.43 Billion | ▲ +0.2 pp |
| 2020 | 90.9% | CN¥5.79 Billion | CN¥525.23 Million | CN¥6.55 Billion | ▼ -2.5 pp |
| 2019 | 93.4% | CN¥5.79 Billion | CN¥382.56 Million | CN¥6.14 Billion | ▼ -2.1 pp |
| 2018 | 95.5% | CN¥5.64 Billion | CN¥254.67 Million | CN¥6.05 Billion | ▲ +0.4 pp |
| 2017 | 95.1% | CN¥5.41 Billion | CN¥265.93 Million | CN¥5.72 Billion | ▲ +0.1 pp |
| 2016 | 95.0% | CN¥5.24 Billion | CN¥263.92 Million | CN¥5.65 Billion | ▲ +0.3 pp |
| 2015 | 94.7% | CN¥4.26 Billion | CN¥225.93 Million | CN¥4.80 Billion | ▲ +6.2 pp |
| 2014 | 88.5% | CN¥1.68 Billion | CN¥192.41 Million | CN¥2.22 Billion | ▼ -9.0 pp |
| 2013 | 97.5% | CN¥1.33 Billion | CN¥32.83 Million | CN¥1.45 Billion | ▼ -0.9 pp |
| 2012 | 98.5% | CN¥1.16 Billion | CN¥17.86 Million | CN¥1.24 Billion | ▼ -0.2 pp |
| 2011 | 98.7% | CN¥1.06 Billion | CN¥13.74 Million | CN¥1.13 Billion | ▲ +10.6 pp |
| 2010 | 88.1% | CN¥176.62 Million | CN¥20.98 Million | CN¥295.77 Million | ▲ +6.7 pp |
| 2009 | 81.4% | CN¥110.01 Million | CN¥20.41 Million | CN¥185.73 Million | ▼ -1.7 pp |
| 2008 | 83.1% | CN¥63.01 Million | CN¥10.64 Million | CN¥122.38 Million | — |